Peer-influenced content. Sources you trust. No registration required. This is HCN.
Cancer Therapy Advisor
The recent study on bevacizumab’s effect on ovarian cancer progression provides valuable insights into its initial benefits and subsequent risks.
Obstetrics & Gynecology August 14th 2023
NEJM Evidence
Join historian Susan W. Wade, Ph.D., in exploring her personal experience with vulvar cancer and participation in an experimental clinical trial. Wade’s firsthand account offers not only medical insights but a deeper understanding of the patient’s psychological journey and a reflection on the future of oncology treatments.
Obstetrics & Gynecology August 1st 2023
OBR Oncology
Selinexor has demonstrated an extraordinary extension in progression-free survival in patients with wild-type TP53 advanced or recurrent endometrial cancer, according to the recent findings from the SIENDO study.
Oncology Learning Network
Dr. Jyoti Mayadev, a professor of Radiation Medicine at University of California San Diego, discussed the treatment of patients with 1B3 cervical cancer at the Society of Gynecological Oncology’s Annual Meeting on Women’s Cancer. The discussion centered around whether to treat patients with primary chemoradiation and brachytherapy or radical surgery. Dr. Mayadev recommends a multidisciplinary approach, but notes that level 1 evidence data from Landoni et al. in 1997 showed no difference in progression-free survivals or overall survivals between radiation therapy and radical hysterectomy in patients with bulky disease, 1B3, and no lymph node disease. Dr. Mayadev discusses the benefits of chemoradiation, including potential toxicity reduction if a patient needs adjuvant therapy after surgery. She also notes that with technologically advanced radiation and brachytherapy, long-term toxicities can be minimized, including genitourinary toxicities at 6-8%, vaginal toxicities at 5%, and fistula at less than 2%. Dr. Mayadev believes that adaptive radiation therapy may further decrease toxicities and increase cure rates for patients with 1B3 cervical cancer. There are ongoing trials for novel therapeutics and adaptive radiation therapy, such as the ARTIA Cervical Trial, which aims to decrease toxicities and collect patient reported outcomes.
Obstetrics & Gynecology May 8th 2023
Roswell Park
In this on-demand webinar, a trio of Roswell Park Comprehensive Cancer Center experts share their wisdom on ovarian, cervical, and endometrial cancers. Dr. Emese Zsiros, Chair of Gynecologic Oncology, hosts the event with presenters Drs. Karen McLean and Katherine LaVinge Mager, Associate Professor of Oncology and Assistant Professor of Oncology in the Department of Gynecologic Oncology, respectively.
Oncology, Medical November 28th 2022
Cancer Therapy Advisor provides a variety of resources, including regimens used to supplement the most recent treatment strategies. Examine all regimens here.
Hematology/Oncology October 7th 2022